These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2340500)

  • 1. Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
    Hauser GJ; McIntosh JK; Travis WD; Rosenberg SA
    Cancer Res; 1990 Jun; 50(12):3503-8. PubMed ID: 2340500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
    McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA
    Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
    Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
    Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
    J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
    Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Augmentation of TNF- and lymphotoxin-mediated cytotoxic effect in the combined use of ACNU and involvement of oxygen free radicals].
    Matsunaga K; Mashiba H
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):452-8. PubMed ID: 2321976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor.
    Zimmerman RJ; Chan A; Leadon SA
    Cancer Res; 1989 Apr; 49(7):1644-8. PubMed ID: 2924312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice.
    Postma NS; Crommelin DJ; Eling WM; Zuidema J
    J Pharmacol Exp Ther; 1999 Jan; 288(1):114-20. PubMed ID: 9862761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of 131I-labeled recombinant human tumor necrosis factor-alpha on the nude mice bearing human hepatoma].
    Long YH; Li YC; Mi YX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):787-92. PubMed ID: 19950584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
    Haranaka K; Sakurai A; Satomi N
    J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action.
    Zimmerman RJ; Marafino BJ; Chan A; Landre P; Winkelhake JL
    J Immunol; 1989 Feb; 142(4):1405-9. PubMed ID: 2915120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of tumor necrosis factor alpha or lymphotoxin on global blood flow, laser Doppler flux, and bioenergetic status of subcutaneous rodent tumors.
    Kluge M; Elger B; Engel T; Schaefer C; Seega J; Vaupel P
    Cancer Res; 1992 Apr; 52(8):2167-73. PubMed ID: 1559220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
    McIntosh JK; Jablons DM; Mulé JJ; Nordan RP; Rudikoff S; Lotze MT; Rosenberg SA
    J Immunol; 1989 Jul; 143(1):162-7. PubMed ID: 2499626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.
    Satomi N; Sakurai A; Haranaka R; Haranaka K
    J Biol Response Mod; 1988 Feb; 7(1):54-64. PubMed ID: 3373234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.
    Gasparri A; Moro M; Curnis F; Sacchi A; Pagano S; Veglia F; Casorati G; Siccardi AG; Dellabona P; Corti A
    Cancer Res; 1999 Jun; 59(12):2917-23. PubMed ID: 10383155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha alters response of lung cancer cells to oxidative stress.
    Pogrebniak HW; Prewitt TW; Matthews WA; Pass HI
    J Thorac Cardiovasc Surg; 1991 Dec; 102(6):904-7. PubMed ID: 1960995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buthionine sulfoximine reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack.
    Le CT; Hollaar L; van der Valk EJ; van der Laarse A
    J Mol Cell Cardiol; 1993 May; 25(5):519-28. PubMed ID: 8104252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.